Safety and Efficacy of Drug Combinations Against Schistosomiasis

Not Applicable

Completed

• Conditions: Parasitic Diseases
• Interventions: Drug: mebendazole + praziquantel; Drug: albendazole + praziquantel

• Registration Number: NCT01050374
• Lead Sponsor: DBL -Institute for Health Research and Development

Brief Summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Study First Submitted: 2008-01-23
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2010-01
• Study First Submitted QC: 2010-01-14
• Last Update Submitted: 2010-01-14
• Study First Posted: 2010-01-15
• Last Update Posted: 2010-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 650

Inclusion Criteria

• Those with an age of 1-15 years of age
• Are infected with schistosomiasis and soil-transmitted helminthiasis
• Whose parent consent and who are willing to participate

Exclusion Criteria

• Those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis
• Those with a history of any serious adverse drug reactions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	mebendazole + praziquantel	mebendazole + praziquantel
1	albendazole + praziquantel	albendazole + praziquantel

Primary Outcome Measures

Name	Time	Method
Efficacy of treatment	6 weeks

Secondary Outcome Measures

Name	Time	Method
Record of adverse reactions	6 weeks

Trial Locations

Locations (1)

Vector Control Division; 🇺🇬 Kampala, Uganda